These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 29550200

  • 1. Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents.
    Angelergues A, Efstathiou E, Gyftaki R, Wysocki PJ, Lainez N, Gonzalez I, Castellano DE, Ozguroglu M, Carbonero IG, Flechon A, Borrega P, Guillot A, Balea BC, Le Moulec S, Esteban E, Munarriz J, Rubio G, Birtle AJ, Delanoy N, Bellmunt J, Oudard S.
    Clin Genitourin Cancer; 2018 Aug; 16(4):e777-e784. PubMed ID: 29550200
    [Abstract] [Full Text] [Related]

  • 2. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.
    Delanoy N, Hardy-Bessard AC, Efstathiou E, Le Moulec S, Basso U, Birtle A, Thomson A, Krainer M, Guillot A, De Giorgi U, Hasbini A, Daugaard G, Bahl A, Chowdhury S, Caffo O, Beuzeboc P, Spaeth D, Eymard JC, Fléchon A, Alexandre J, Helissey C, Butt M, Priou F, Lechevallier É, Deville JL, Goupil MG, Morales R, Thiery-Vuillemin A, Gavrikova T, Barthelemy P, Sella A, Fizazi K, Baciarello G, Fererro JM, Laguerre B, Verret B, Hans S, Oudard S.
    Eur Urol Oncol; 2018 Dec; 1(6):467-475. PubMed ID: 31158090
    [Abstract] [Full Text] [Related]

  • 3. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
    van Soest RJ, Nieuweboer AJ, de Morrée ES, Chitu D, Bergman AM, Goey SH, Bos MM, van der Meer N, Hamberg P, de Wit R, Mathijssen RH, Dutch Uro-Oncology Studygroup (DUOS).
    Eur J Cancer; 2015 Nov; 51(17):2562-9. PubMed ID: 26278646
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.
    Thibault C, Eymard JC, Birtle A, Krainer M, Baciarello G, Fléchon A, Le Moulec S, Spaeth D, Laguerre B, Caffo O, Deville JL, Beuzeboc P, Hasbini A, Gross-Goupil M, Helissey C, Bennamoun M, Hardy-Bessard AC, Oudard S.
    Eur J Cancer; 2018 Jul; 97():41-48. PubMed ID: 29636272
    [Abstract] [Full Text] [Related]

  • 5. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [Abstract] [Full Text] [Related]

  • 6. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES.
    Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
    [Abstract] [Full Text] [Related]

  • 7. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
    Barata P, Emamekhoo H, Mendiratta P, Koshkin V, Tyler A, Ornstein M, Rini BI, Gilligan T, Kyriakopoulos C, Garcia JA.
    Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
    [Abstract] [Full Text] [Related]

  • 8. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.
    Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS.
    Med Oncol; 2017 Aug 10; 34(9):160. PubMed ID: 28795333
    [Abstract] [Full Text] [Related]

  • 9. Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer.
    Caffo O, Wissing M, Bianchini D, Bergman A, Thomsen FB, Schmid S, Yu EY, Bournakis E, Sella A, Zagonel V, De Giorgi U, Tucci M, Gelderblom H, Galli L, Pappagallo G, Bria E, Sperduti I, Oudard S, CASTOR study investigators.
    Clin Genitourin Cancer; 2020 Feb 10; 18(1):69-76.e4. PubMed ID: 31767448
    [Abstract] [Full Text] [Related]

  • 10. Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents.
    Bando Y, Hinata N, Terakawa T, Furukawa J, Harada KI, Nakano Y, Fujisawa M.
    Med Oncol; 2017 Aug 17; 34(9):163. PubMed ID: 28819719
    [Abstract] [Full Text] [Related]

  • 11. The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study.
    Okita K, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Ito A, Tsuchiya N, Arai Y, Habuchi T, Ohyama C.
    Clin Genitourin Cancer; 2020 Apr 17; 18(2):e103-e111. PubMed ID: 31810867
    [Abstract] [Full Text] [Related]

  • 12. Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer.
    Robin G, Basappa NS, North S, Ghosh S, Kolinsky M.
    Curr Oncol; 2024 Aug 29; 31(9):5080-5087. PubMed ID: 39330003
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice.
    Mizokami A, Nishimoto K, Matsuyama H, Ichikawa T, Takahashi S, Shiina H, Hashine K, Sugiyama Y, Kamiyama M, Enokida H, Nakajima K.
    Anticancer Res; 2022 Mar 29; 42(3):1465-1475. PubMed ID: 35220240
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Jang HS, Koo KC, Cho KS, Chung BH.
    Yonsei Med J; 2016 Sep 29; 57(5):1070-8. PubMed ID: 27401636
    [Abstract] [Full Text] [Related]

  • 16. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
    Fan L, Wang R, Chi C, Cai W, Zhang Y, Qian H, Shao X, Wang Y, Xu F, Pan J, Zhu Y, Shangguan X, Zhou L, Dong B, Xue W.
    Prostate; 2018 Mar 29; 78(4):250-256. PubMed ID: 29285775
    [Abstract] [Full Text] [Related]

  • 17. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
    van Soest RJ, de Morrée ES, Shen L, Tannock IF, Eisenberger MA, de Wit R.
    Eur Urol; 2014 Aug 29; 66(2):330-6. PubMed ID: 23957945
    [Abstract] [Full Text] [Related]

  • 18. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM, Hotte SJ, Saad F, Alekseev B, Matveev V, Fléchon A, Gravis G, Joly F, Chi KN, Malik Z, Blumenstein B, Stewart PS, Jacobs CA, Fizazi K.
    Lancet Oncol; 2017 Nov 29; 18(11):1532-1542. PubMed ID: 29033099
    [Abstract] [Full Text] [Related]

  • 19. Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer.
    Pobel C, Auclin E, Teyssonneau D, Laguerre B, Cancel M, Boughalem E, Noel J, Brachet PE, Maillet D, Barthelemy P, Helissey C, Thibault C, Oudard S.
    Cancer Med; 2021 Sep 29; 10(18):6304-6309. PubMed ID: 34382352
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
    Pond GR, Armstrong AJ, Galsky MD, Wood BA, Leopold L, Sonpavde G.
    Urol Oncol; 2013 Nov 29; 31(8):1457-63. PubMed ID: 22552048
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.